The SyncroPatch 384 is installed at the FDA for cardiac safety pharmacology studies
Nanion is pleased to announce that a SyncroPatch 384 instrument has been installed at the Food and Drug Administration (…
Newsrooms
Nanion's SyncroPatch is Preferred Technology for Patch Clamp-Based High Throughput Screening
According to a recent survey among automated patch clamp users, performed by HTStec Ltd., respondents favour Nanion’s in…
Nanion Technologies Appoints James Costantin as Director of Customer Relations
Dr. Costantin has a solid and highly impressive track record in customer relation management, in-depth knowledge of ion…
Cardiac Researchers at National Heart Centre Singapore Acquire First SyncroPatch 384/768PE in Asia
Scientific Director Dr. Winston Shim and his research group aim at restoring compromised heart tissue by using stem cell…
Nanion TWIns With Stem Cells as New facilities Are Opened in Japan and USA
Nanion Technologies, an innovative German-based company providing high quality devices for ion channel research and drug…
Prestigious Academic Facility at Northwestern University Acquires the SyncroPatch 384/768PE
The SyncroPatch 384/768PE offers the highest throughput in automated patch clamping history. The SyncroPatch 384/768PE f…
Das Team der Nanion Technologies für Deutschen Zukunftspreis nominiert
Das Management Team der Nanion Technologies GmbH ist eine von drei Nominierten für den Deutschen Zukunftspreis, den Prei…
Successful Introduction of a Novel Patch Clamp-Based HTS-System Through Collaboration Between Nanion and Beckman Coulter
Nanion recently introduced the SyncroPatch 384 Patch Engine (PE), an instrument for HTS-compatible ion channel screening…
Nanion Starts Shipping the SyncroPatch 384PE - a Revolutionary Instrument for Giga-Seal, Automated Patch Clamp-Based Ion Channel Drug Screening
The brand-new SyncroPatch 384 Patch Engine (PE) now released by Nanion Technologies propels ion channel drug discovery t…
